Provides cancer genomic testing for patients and drug developers, plus sequencing services for diagnostic businesses and population-research programs.
10-K for FY2025, filed Feb 26, 2026Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect…View ↗
We perform whole exome sequencing ("WES") of cancer tissue and matched blood samples for diagnostic companies as an input to their products.View ↗
We perform whole genome sequencing ("WGS") on human samples for research projects, such as population sequencing initiatives.View ↗
Customers buy genomic testing services through contracts, statements of work, or purchase orders; payment is due after invoicing.
10-K for FY2025, filed Feb 26, 2026
$69.6M
10-K for FY2025, filed Feb 26, 2026
$69.6M ↗
Drug-development and diagnostic organizations, research institutions and government programs, and cancer patients buy its tests. Personalis sells through a small direct sales force and co-commercializes NeXT Personal Dx with Tempus.
10-K for FY2025, filed Feb 26, 2026Markets and DistributionView ↗
10-K for FY2025, filed Feb 26, 2026
We currently derive a significant portion of our revenue from Moderna by providing genomic testing in its ongoing clinical trials for its…View ↗
No. It lost $81.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$33.8MView ↗
8-K, filed Jul 20, 2026
On July 20, 2026, Personalis, Inc., a Delaware corporation (“Personalis” or the “Company”), entered into an Agreement and Plan of Merger…View ↗
Shrinking. Revenue fell 19% in 4 years, from $85.5M in FY2021 to $69.6M in FY2025, about 5% a year.
Clinical diagnostics
The older report described clinical diagnostics as an area for future expansion after launching new offerings; the latest report details tests ordered for patients, including personalized monitoring and tumor profiling.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Today, our platforms are routinely used by many of the largest oncology-focused pharmaceutical companies for analysis of patient samples in…View ↗
Competes with Adela, Caris Life Sciences, DELFI Diagnostics, Exact Sciences, Foresight Diagnostics, Foundation Medicine, GRAIL, Guardant Health, Haystack Oncology, Laboratory Corporation of America Holdings, MedGenome, Myriad, Natera, NeoGenomics, Predicine, SAGA Diagnostics, Veracyte, Illumina, and Thermo Fisher Scientific
10-K for FY2025, filed Feb 26, 2026Our principal competition comes from commercial and academic organizations that employ various approaches to produce test results or…View ↗
Loading...